Navigation Links
Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial
Date:6/23/2008

NAGOYA, Japan, June 23 /PRNewswire/ -- Although previous studies suggest that orthokeratology contact lens wear slows the axial length growth of the eye in children with progressing myopia, some limitations in the methodology employed have been evident. Using a rigorous study design and precise optical measuring instruments, Menicon Co., Ltd. and the Novovision Clinic in Madrid are undertaking the Myopia Control with Orthokeratology contact lenses in Spain (MCOS) study to compare the axial length growth between white European myopic children wearing orthokeratology contact lenses (OK) and distance single-vision spectacles (SP) over a 2-year period. In this prospective, single-centre clinical trial, sixty-two subjects 6 to 12 years of age, and with myopia of -0.75 to -4.00 D and astigmatism < =1.00 D were randomly allocated wear OK or SP correction. Measurements of axial length (using partial coherence interferometry, Zeiss IOLMaster), anterior chamber depth, corneal topography, cycloplegic refraction and visual acuity are being performed at 6-month intervals. To date, no subjects have withdrawn from the study, no adverse events were evident and no contact lens fitting modifications were required in the OK group. The MCOS study offers a number of notable features: a prospective design; well matched samples and high resolution ocular biometry measures, which collectively should elucidate whether OK contact lens wear is a feasible method of myopia control.

"The MCOS study aims, using a rigorous study design and precise optical measuring instruments, at elucidating whether orthokeratology lens wear slows the axial length growth of the eye in children with progressing myopia. This study is of special relevance taking into account that the prevalence of myopia has increased substantially over recent decades and now is approaching 10-25% and 60-80% in industrialized societies of the West and East, respectively," commented Dr. Jacinto Santodomingo, Global Professional Relations Manager for Menicon Co., Ltd.

"We have been fitting orthokeratology lenses in our clinic for several years, during which we observed that myopia tended to progress less in children wearing orthokeratology lenses compared to children wearing other modalities of visual correction. We are delighted to participate in this unique clinical trial, which should prove whether we are correct about our preliminary observations," added Mr. Cesar Villa, Director of Optometry at Novovision.

About Menicon:

Menicon Co., Ltd. (http://www.menicon.com), founded by Mr. Kyoichi Tanaka in 1951, is Japan's first and largest contact lens manufacturer, and now is represented in over 30 countries. Menicon is a manufacturer dedicated to all areas of soft and GP contact lens related businesses including material development, lens designing, and manufacturing of contact lenses and care solutions. Menicon is a world-leader in the development of hyper-Dk GP (Menicon Z) and soft contact lenses (Menicon PremiO).

Contact:

Toshio Matsushima

Global Business Operations

Menicon Co., Ltd.

Phone: +81-52-937-5021

Fax: +81-52-935-1121

E-mail: matsushima@menicon-net.co.jp

URL: http://www.menicon.com


'/>"/>
SOURCE Menicon Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
5. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
6. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
9. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
10. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... EAST HANOVER, N.J. , April 19, 2017 ... study conducted by the National Heart, Lung, and ... Health (NIH) demonstrating that 58% of patients with ... at six months when treated with eltrombopag at ... treatment 1 . The study evaluated three sequential ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
Breaking Medicine Technology:
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... election process has been in place since the RBMA was founded in 1968 with ... succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... America (UCAOA) and College of Urgent Care Medicine will host industry leaders for ... and speakers will help those in the industry adapt to the issues currently ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
Breaking Medicine News(10 mins):